Ligand Pharma (LGND) Tops Q2 EPS by 42c
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $285.60 --0%
EPS Growth %: -24.9%
Financial Fact:
Weighted average number of common shares - diluted: 23M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -24.9%
Financial Fact:
Weighted average number of common shares - diluted: 23M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Ligand Pharma (NASDAQ: LGND) reported Q2 EPS of $2.37, $0.42 better than the analyst estimate of $1.95. Revenue for the quarter came in at $83.7 million versus the consensus estimate of $62.93 million.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James Downgrades Phreesia Inc. (PHR) to Market Perform
- DA Davidson Downgrades Best Buy (BBY) to Neutral
- Boston Scientific unlikely to meet forecasts after cyber attack - Bloomberg
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
